AbbVie Inc header image

AbbVie Inc

ABBV

Equity

ISIN null / Valor 20145667

New York Stock Exchange, Inc (2026-10-05)

USD 265.76+1.12%

AbbVie Inc
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

AbbVie Inc. is a global biopharmaceutical company dedicated to researching, developing, and marketing innovative medicines and medical solutions. With a workforce of over 50,000 employees across more than 70 countries, AbbVie focuses on addressing complex health challenges and improving the quality of life for people around the world. The company has a significant presence in research and development (R&D) and manufacturing, with facilities in approximately 20 countries. AbbVie's portfolio includes treatments for over 75 conditions, and its products reach around 50 million people annually in 175 countries. The company also emphasizes collaboration, maintaining over 250 partnerships with biotech firms, universities, nonprofits, and government organizations to advance scientific discovery. AbbVie's commitment to innovation is underscored by its development pipeline, which includes more than 80 compounds, devices, or indications.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

13.6%1Y

80.2%3Y

143%5Y

Performance

26.4%1Y

25.1%3Y

23.6%5Y

Volatility

469629 M

Market cap (USD)

7,544,505

Daily traded volume (Shares)

177.34 / 175.6

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.50

2 votes

Performance:

5.00

Innovation:

4.50

Society:

3.50

Nature:

3.50

Lou Charlotte Wehrli

Switzerland, 15 May 2024

Interesting Stock and business model. Since people are obsessed with health and beauty, there is potential there.

Luba Schoenig

Switzerland, 15 May 2024

AbbVie Inc. has demonstrated robust financial health in its first-quarter 2024 results.

EQUITIES OF THE SAME SECTOR

Oncopeptides AB

Oncopeptides AB Valor: 35671972

Annual Return

-50%0%+50%

Risk level

110

-2.18%SEK 2.06

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited Valor: 11500585

Annual Return

-50%0%+50%

Risk level

110

1.98%INR 831.15

Vitrolife AB

Vitrolife AB Valor: 41707777

Annual Return

-50%0%+50%

Risk level

110

-2.34%SEK 89.65

Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited Valor: 11650098

Annual Return

-50%0%+50%

Risk level

110

-1.31%INR 8,010.00

Royalty Pharma PLC

Royalty Pharma PLC Valor: 55041695

Annual Return

-50%0%+50%

Risk level

110

-0.87%USD 56.66

AstraZeneca PLC

AstraZeneca PLC Valor: 982352

Annual Return

-50%0%+50%

Risk level

110

-0.89%GBP 117.64

Envista Holdings Corporation

Envista Holdings Corporation Valor: 49153522

Annual Return

-50%0%+50%

Risk level

110

-0.51%USD 23.34

Humana Inc

Humana Inc Valor: 940174

Annual Return

-50%0%+50%

Risk level

110

4.05%USD 404.07

Haemonetics Corp

Haemonetics Corp Valor: 937449

Annual Return

-50%0%+50%

Risk level

110

0.00%USD 104.68

DENTSPLY SIRONA Inc

DENTSPLY SIRONA Inc Valor: 31773200

Annual Return

-50%0%+50%

Risk level

110

-1.27%USD 8.56

SIX

FactSet

Clearbit

Logos provided by Clearbit